Small Company, Big Impact: A Roadmap to Commercialization and Transforming a Therapeutic Category

Session details:

Launching a medicine as a lean independent biotech is hard, but it’s possible with a strategic approach rooted in a clear development and commercialization path, and executing with discipline. In this fireside chat, Unicycive Therapeutics’ CEO Shalabh Gupta and EVP of Corporate Strategy Doug Jesmasek will share a practical playbook for building and scaling efficiently, using chronic kidney disease (CKD) and a crowded market as a real-world case study, including:

• The dynamics of a concentrated market to create a viable, targeted launch strategy with a streamlined infrastructure.
• The importance of a resilient and efficient company culture to navigate the necessary regulatory and clinical milestones on the path to commercialization.